UA85079C2 - Derivatives of n-(1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity - Google Patents

Derivatives of n-(1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity

Info

Publication number: UA85079C2
Authority: UA; Ukraine
Prior art keywords: unsubstituted; alkyl; substituted; sulphonamide; pyrazol
Prior art date: 2004-01-12

Application number

UAA200608995A

Other languages

English (en)

Inventor

Франсис Барт

Кристиан Конжи

Серж Мартинес

Мюриэлль Ринальди-Кармона

Original Assignee

Санофи-Авентис

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-01-12

Filing date

2005-01-07

Publication date

2008-12-25

2005-01-07 Application filed by Санофи-Авентис filed Critical Санофи-Авентис

2008-12-25 Publication of UA85079C2 publication Critical patent/UA85079C2/ru

Links

FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 title 1
229940124530 sulfonamide Drugs 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 5
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
239000003814 drug Substances 0.000 abstract 2
238000002360 preparation method Methods 0.000 abstract 2
WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical compound F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
125000004981 cycloalkylmethyl group Chemical group 0.000 abstract 1
125000005843 halogen group Chemical group 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
125000001544 thienyl group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Addiction (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Anesthesiology (AREA)
Child & Adolescent Psychology (AREA)

UAA200608995A 2004-01-12 2005-01-07 Derivatives of n-(1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity UA85079C2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0400257A FR2864958B1 (fr)	2004-01-12	2004-01-12	Derive de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique.

Publications (1)

Publication Number	Publication Date
UA85079C2 true UA85079C2 (en)	2008-12-25

Family

ID=34684951

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200608995A UA85079C2 (en)	2004-01-12	2005-01-07	Derivatives of n-(1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity

Country Status (31)

Country	Link
US (1)	US7294645B2 (ru)
EP (1)	EP1720837B1 (ru)
JP (1)	JP4723514B2 (ru)
KR (1)	KR20060105050A (ru)
CN (1)	CN1910157A (ru)
AR (1)	AR047096A1 (ru)
AT (1)	ATE465995T1 (ru)
AU (1)	AU2005209441B2 (ru)
CA (1)	CA2551141C (ru)
CR (1)	CR8468A (ru)
CY (1)	CY1110651T1 (ru)
DE (1)	DE602005020907D1 (ru)
DK (1)	DK1720837T3 (ru)
EC (1)	ECSP066695A (ru)
ES (1)	ES2344850T3 (ru)
FR (1)	FR2864958B1 (ru)
HR (1)	HRP20100283T8 (ru)
IL (1)	IL176710A0 (ru)
MA (1)	MA28422B1 (ru)
NO (1)	NO20063621L (ru)
NZ (1)	NZ548442A (ru)
PL (1)	PL1720837T3 (ru)
PT (1)	PT1720837E (ru)
RS (1)	RS51365B (ru)
RU (1)	RU2366657C2 (ru)
SI (1)	SI1720837T1 (ru)
TN (1)	TNSN06203A1 (ru)
TW (1)	TWI323255B (ru)
UA (1)	UA85079C2 (ru)
WO (1)	WO2005073197A1 (ru)
ZA (1)	ZA200605657B (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7030141B2 (en) *	2001-11-29	2006-04-18	Christopher Franklin Bigge	Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
FR2880023B1 (fr)	2004-12-23	2007-02-23	Sanofi Aventis Sa	Derives de n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine leur preparation et leur application en therapeutique
FR2880890B1 (fr) *	2005-01-19	2007-03-30	Sanofi Aventis Sa	Derives de n-[(4,5-diphenyl-2-thienyl)methyl]sulfonamide, leur preparation et leur application en therapeutique
FR2881744B1 (fr) *	2005-02-09	2007-04-27	Sanofi Aventis Sa	Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique
FR2894579B1 (fr) *	2005-12-12	2008-01-18	Sanofi Aventis Sa	Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique.
FR2894578B1 (fr) *	2005-12-12	2008-02-01	Sanofi Aventis Sa	Derives heterocycliques, leur preparation et leur application en therapeutique.
EP1829867A1 (en) *	2006-03-03	2007-09-05	Laboratorios Del Dr. Esteve, S.A.	Imidazole compounds having pharmaceutical activity towards the sigma receptor
FR2899899A1 (fr) *	2006-04-14	2007-10-19	Sanofi Aventis Sa	Derives d'aminomethyl pyridine, leur preparation et leur application en therapeutique
EP1878723B1 (fr) *	2006-07-11	2010-05-26	Sanofi-Aventis	Dérivés de N-[(1,5-diphényl-1H-pyrazol-3-yl)méthyl]sulfonamide antagonistes des récepteurs CB1 des cannabinoïdes
JP2008019205A (ja) *	2006-07-12	2008-01-31	Sanofi-Aventis	Ｎ−［（１，５−ジフェニル−１ｈ−ピラゾール−３−イル）メチル］スルホンアミド誘導体、その調製法および治療におけるその応用
US7297710B1 (en) *	2006-07-12	2007-11-20	Sanofi-Aventis	Derivatives of N-[(1,5-diphenyl-1H-pyrazol-3-yl)methyl]sulfonamide, their preparation and their application in therapeutics
WO2008062424A2 (en) *	2006-07-31	2008-05-29	Cadila Healthcare Limited	Substituted 4,5-dihydro-1h-pyrazole derivatives as cannabinoid modulators
US7875647B2 (en)	2006-09-29	2011-01-25	Green Cross Corporation	Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists
EP1911747A1 (en) *	2006-10-11	2008-04-16	Laboratorios del Dr. Esteve S.A.	Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators
FR2911136B1 (fr)	2007-01-05	2009-02-20	Sanofi Aventis Sa	Derives de n-(4-cyano-1h-pyrazol-3-yl)methylamine substitues leur preparation et leur application en therapeutique.
FR2919184A1 (fr) *	2007-07-26	2009-01-30	Sanofi Aventis Sa	L'acide 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4- methylpyrazole-3-carboxylique, ses esters, ses sels pharmaceutiquement acceptables et leurs solvates pour leur utilisation comme medicament.
CA2882127A1 (en) *	2012-08-16	2014-02-20	Janssen Pharmaceutica Nv	Pyrrolopyrazoles as n-type calcium channel blockers
SG11201501130PA (en)	2012-08-16	2015-04-29	Janssen Pharmaceutica Nv	Substituted pyrazoles as n-type calcium channel blockers
RU2664705C2 (ru) *	2013-01-17	2018-08-21	Ф. Хоффманн-Ля Рош Аг	Агонисты рецептора окситоцина для лечения заболеваний центральной нервной системы
US9453002B2 (en)	2013-08-16	2016-09-27	Janssen Pharmaceutica Nv	Substituted imidazoles as N-type calcium channel blockers
KR101685993B1 (ko) *	2014-05-15	2016-12-13	한국과학기술연구원	전압개폐 칼슘이온채널 억제 활성화능을 갖는 ｎ-(피라졸릴메틸)아릴설폰아마이드 화합물 및 이를 포함하는 약학적 조성물
AU2017260706B2 (en)	2016-05-04	2023-05-11	Inmed Pharmaceuticals Inc.	Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
EP3684353A4 (en)	2017-09-22	2021-06-23	Inmed Pharmaceuticals Inc.	TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USES FOR PAIN TREATMENT
WO2022109292A1 (en) *	2020-11-20	2022-05-27	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Methods and materials for inhibiting cb1 activity
WO2025090133A1 (en)	2023-10-23	2025-05-01	Inmed Pharmaceuticals Inc.	Compositions and methods for use of cannabinol compounds in neuroprotection
WO2025090587A1 (en)	2023-10-23	2025-05-01	Inmed Pharmaceuticals Inc.	Cannabinoids compounds and their use in the treatment of neuronal disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2692575B1 (fr) *	1992-06-23	1995-06-30	Sanofi Elf	Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) *	1993-12-02	1996-03-01	Sanofi Sa	N-pipéridino-3-pyrazolecarboxamide substitué.
RU2165542C2 (ru) *	1999-04-27	2001-04-20	Открытое акционерное общество "АВТОВАЗ"	Модульный агрегат топливоподачи системы питания двигателя транспортного средства

2004
- 2004-01-12 FR FR0400257A patent/FR2864958B1/fr not_active Expired - Fee Related
2005
- 2005-01-07 CN CNA2005800022298A patent/CN1910157A/zh active Pending
- 2005-01-07 RS RSP-2010/0336A patent/RS51365B/sr unknown
- 2005-01-07 JP JP2006548341A patent/JP4723514B2/ja not_active Expired - Fee Related
- 2005-01-07 DE DE602005020907T patent/DE602005020907D1/de not_active Expired - Lifetime
- 2005-01-07 KR KR1020067016046A patent/KR20060105050A/ko not_active Ceased
- 2005-01-07 CA CA2551141A patent/CA2551141C/fr not_active Expired - Fee Related
- 2005-01-07 AT AT05717379T patent/ATE465995T1/de active
- 2005-01-07 DK DK05717379.1T patent/DK1720837T3/da active
- 2005-01-07 AU AU2005209441A patent/AU2005209441B2/en not_active Ceased
- 2005-01-07 WO PCT/FR2005/000031 patent/WO2005073197A1/fr not_active Ceased
- 2005-01-07 ES ES05717379T patent/ES2344850T3/es not_active Expired - Lifetime
- 2005-01-07 PT PT05717379T patent/PT1720837E/pt unknown
- 2005-01-07 PL PL05717379T patent/PL1720837T3/pl unknown
- 2005-01-07 RU RU2006129297/04A patent/RU2366657C2/ru not_active IP Right Cessation
- 2005-01-07 ZA ZA200605657A patent/ZA200605657B/xx unknown
- 2005-01-07 NZ NZ548442A patent/NZ548442A/en not_active IP Right Cessation
- 2005-01-07 UA UAA200608995A patent/UA85079C2/ru unknown
- 2005-01-07 SI SI200531060T patent/SI1720837T1/sl unknown
- 2005-01-07 EP EP05717379A patent/EP1720837B1/fr not_active Expired - Lifetime
- 2005-01-07 HR HR20100283T patent/HRP20100283T8/xx unknown
- 2005-01-10 AR ARP050100070A patent/AR047096A1/es unknown
- 2005-01-11 TW TW094100683A patent/TWI323255B/zh not_active IP Right Cessation
2006
- 2006-06-19 MA MA29118A patent/MA28422B1/fr unknown
- 2006-06-21 CR CR8468A patent/CR8468A/es unknown
- 2006-06-23 TN TNP2006000203A patent/TNSN06203A1/en unknown
- 2006-07-05 IL IL176710A patent/IL176710A0/en not_active IP Right Cessation
- 2006-07-06 US US11/428,928 patent/US7294645B2/en not_active Expired - Lifetime
- 2006-07-11 EC EC2006006695A patent/ECSP066695A/es unknown
- 2006-08-10 NO NO20063621A patent/NO20063621L/no not_active Application Discontinuation
2010
- 2010-06-03 CY CY20101100491T patent/CY1110651T1/el unknown

Also Published As

Publication number	Publication date
HRP20100283T8 (hr)	2010-10-31
CA2551141A1 (fr)	2005-08-11
NO20063621L (no)	2006-10-10
ES2344850T3 (es)	2010-09-08
KR20060105050A (ko)	2006-10-09
NZ548442A (en)	2009-10-30
AU2005209441A1 (en)	2005-08-11
HRP20100283T1 (hr)	2010-08-31
EP1720837B1 (fr)	2010-04-28
CN1910157A (zh)	2007-02-07
JP2007517839A (ja)	2007-07-05
EP1720837A1 (fr)	2006-11-15
TNSN06203A1 (en)	2007-11-15
JP4723514B2 (ja)	2011-07-13
RU2006129297A (ru)	2008-02-20
PL1720837T3 (pl)	2010-09-30
ATE465995T1 (de)	2010-05-15
DK1720837T3 (da)	2010-08-23
US20070021486A1 (en)	2007-01-25
DE602005020907D1 (de)	2010-06-10
ECSP066695A (es)	2006-10-31
RS51365B (sr)	2011-02-28
PT1720837E (pt)	2010-05-14
WO2005073197A1 (fr)	2005-08-11
CA2551141C (fr)	2011-06-07
IL176710A0 (en)	2006-10-31
US7294645B2 (en)	2007-11-13
TW200535135A (en)	2005-11-01
ZA200605657B (en)	2007-12-27
CR8468A (es)	2007-03-06
AU2005209441B2 (en)	2010-12-23
MA28422B1 (fr)	2007-02-01
FR2864958B1 (fr)	2006-02-24
CY1110651T1 (el)	2015-06-10
AR047096A1 (es)	2006-01-04
TWI323255B (en)	2010-04-11
RU2366657C2 (ru)	2009-09-10
SI1720837T1 (sl)	2010-08-31
FR2864958A1 (fr)	2005-07-15

Publication	Publication Date	Title
UA85079C2 (en)	2008-12-25	Derivatives of n-(1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity
DK1713475T3 (da)	2008-12-01	1,3,5-trisubstituerede 4,5-dihydro-1H-pyrazol-derivater med CB1-antagonistisk aktivitet
NO20071642L (no)	2007-06-01	N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
NO20070224L (no)	2007-04-02	2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
TR200102338T2 (tr)	2002-07-22	Siklik ikame edilmiş bağlı pirolokarbazoller ve izoindolonlar.
TW200745034A (en)	2007-12-16	New compounds
NO20082096L (no)	2008-05-29	Azaindol-2-karboksamidderivativer
MXPA05007115A (es)	2005-11-16	Nuevos agonistas inversos del receptor cb 1.
DK1585493T3 (da)	2010-12-06	Triazinderivater som UV-absorbenter
UA96947C2 (ru)	2011-12-26	Производные циннамоил-пиперазина и их применение как антагонистов par-1
DK1401432T3 (da)	2006-02-06	Natriumkanalmodulerende imidazolderivater
NO20082214L (no)	2008-07-31	1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
WO2006136859A3 (en)	2007-04-05	Indoli zine derivatives and their use as crth2 antagonists
MY146939A (en)	2012-10-15	Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics
EP1854789A4 (en)	2009-06-17	CHINAZOLINE DERIVATIVE WITH TYROSINE KINASE HEMMENDER EFFECT
FR2847899B1 (fr)	2006-04-28	Derives d'indole-3-carboxamide, leur preparation et leur application en therapeutique
TNSN07439A1 (en)	2009-03-17	Derivatives of,4,5 - diarylpyrrole, preparation method thereof and use of same in therapeutics
IL178032A0 (en)	2006-12-31	An improved process for the preparation of n-([1,2,4-]triazolopyrimidin-2-yl)aryl sulfonamides
MY148980A (en)	2013-06-28	Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics
EA200700179A1 (ru)	2007-08-31	Производные пиррола, их получение и их применение в терапии
TW200626130A (en)	2006-08-01	5-membered heterocycle derivatives
EA200700891A1 (ru)	2007-08-31	Производные пиридина, их получение и их применение в терапии
TW200631952A (en)	2006-09-16	Benzdioxan piperazine derivatives with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
ATE437626T1 (de)	2009-08-15	Kosmetische zusammensetzung mit polyorganosiloxan und ihre anwendung
TW200633987A (en)	2006-10-01	Phenylpiperazines with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites